CLINUVEL’s Study Highlights Need for Combined Therapy in Vitiligo Treatment

Clinuvel Pharmaceuticals ( (AU:CUV) ) has provided an update.

CLINUVEL announced the results of its Phase II pilot study, CUV104, which evaluated SCENESSE® as a monotherapy for vitiligo, demonstrating that it was ineffective in repigmenting skin without adjunct narrowband ultraviolet B (NB-UVB) phototherapy. The study’s findings confirm the necessity of combining afamelanotide with NB-UVB for effective treatment, influencing the company’s future study designs and regulatory submissions. This development underscores CLINUVEL’s commitment to advancing treatment options for vitiligo, particularly for patients with darker skin types, and aligns with its strategic focus on innovative therapies.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$46.35 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

More about Clinuvel Pharmaceuticals

CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for specialized populations. The company is a pioneer in photomedicine and melanocortin peptides, with its lead therapy, SCENESSE® (afamelanotide 16mg), approved for systemic photoprotection in various regions including Europe, the USA, Israel, and Australia.

Average Trading Volume: 101,266

Technical Sentiment Signal: Sell

Current Market Cap: A$491.7M

Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.